Evidence map›Paper›PMID 38319035›Full record

ArticleThe American journal on addictions2024

The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report.

Amber N Edinoff, David B Hathaway, David Martinez Garza, Jordan H Rosen, Joji Suzuki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal on addictions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amber N EdinoffDivision of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts, USA.ORCID 0000-0001-7436-6206
David B HathawayDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
David Martinez GarzaDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Jordan H RosenDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Joji SuzukiDepartment of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-5659-6147

Funding

Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trialR21AA030372 · NIAAA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R, SUZUKI, JOJI · 2022 to 2023
$470k
NIAAA NIH HHS R21 AA030372NIAAA NIH HHS R21AA030372
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe decision to initiate pharmacotherapy for alcohol withdrawal is typically based on examining self-reported use of alcohol and symptoms of withdrawal. Phosphatidylethanol (PEth) is a biomarker that could aim in clinical decision-making in withdrawal management.

methodsThis report describes three cases highlighting the potential clinical utility of PEth in caring for individuals at risk for alcohol withdrawal.

resultsTwo of the cases received phenobarbital when their PEth showed that the risk of withdrawal was low and one case where PEth could have shown this was needed. The results were only available in a delayed fashion, however, could have been useful in informing clinical care. DISCUSSION AND

conclusionPEth can be a useful tool if available without delay. PEth can be used to quickly rule out alcohol withdrawal and avoid misdiagnoses and prolonged hospital stays. SCIENTIFIC SIGNIFICANCE: This is a clinical case study available looking at PEth and withdrawal in hospitalized patients. It proposes that PEth can be used as a way to quickly rule out alcohol withdrawal to avoid misdiagnoses and the possibility of a prolonged hospital stay.

Indexed as

AlcoholismGlycerophospholipidsSubstance Withdrawal SyndromeAlcohol DrinkingBiomarkersEthanolHumansBiomarkersEthanolGlycerophospholipidsphosphatidylethanol

Identifiers

PMID38319035
PMCPMC11032224

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.